Getting oncolytic virus therapies off the ground

Cancer Cell

Volumn 4, Issue 1, 2003, Pages 7-11

  Bell, John C ^a   Lichty, Brian ^a   Stojdl, David ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; GENE PRODUCT; HEAT SHOCK PROTEIN 90; INTERFERON; MESSENGER RNA; ONCOLYTIC VIRUS; ONYX 015; PROTEIN P53; PROTEIN PV701; RAS PROTEIN; SNAKE VENOM ANTISERUM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR;

5' UNTRANSLATED REGION; APOPTOSIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL DIVISION; CELL GROWTH; CLINICAL TRIAL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; GENE EXPRESSION; GENETIC MANIPULATION; HERPES VIRUS; HUMAN; IMMUNITY; LIVER METASTASIS; MYXOMA VIRUS; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; SUICIDE GENE; TRANSGENE; TREATMENT OUTCOME; TUMOR CELL CULTURE; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIROGENESIS; VIRUS ATTENUATION; VIRUS GENE; VIRUS STRAIN;

ADENOVIRIDAE; HERPESVIRIDAE; MYXOMA VIRUS; SERPENTES; VESICULAR STOMATITIS VIRUS;

EID: 0041848214     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00170-3     Document Type: Conference Paper

References (46)

1. Babiss L.E., Ginsberg H.S., Darnell J.E. Jr. Adenovirus E1B proteins are required for accumulation of late viral mRNA and for effects on cellular mRNA translation and transport. Mol. Cell. Biol. 5:1985;2552-2558.
2. Bangma C.H. Targeting of adenoviral vectors for gene therapy of prostate cancer. Prostate Cancer Prostatic Dis. 3:2000;308-312.
3. Barnett B.G., Tillman B.W., Curiel D.T., Douglas J.T. Dual targeting of adenoviral vectors at the levels of transduction and transcription enhances the specificity of gene expression in cancer cells. Mol. Ther. 6:2002;377-385.
4. Bauzon M., Castro D., Karr M., Hawkins L.K., Hermiston T.W. Multigene expression from a replicating adenovirus using native viral promoters. Mol. Ther. 7:2003;526-534.
5. Bergmann M., Romirer I., Sachet M., Fleischhacker R., Garcia-Sastre A., Palese P., Wolff K., Pehamberger H., Jakesz R., Muster T. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res. 61:2001;8188-8193.
6. Bucheit A.D., Kumar S., Grote D.M., Lin Y., von Messling V., Cattaneo R.B., Fielding A.K. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol. Ther. 7:2003;62-72.
7. Doronin K., Toth K., Kuppuswamy M., Ward P., Tollefson A.E., Wold W.S. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74:2000;6147-6155.
8. Doronin K., Toth K., Kuppuswamy M., Krajcsi P., Tollefson A.E., Wold W.S. Overexpression of the ADP (E3-11.6K) protein increases cell lysis and spread of adenovirus. Virology. 305:2003;378-387.
9. Freytag S.O., Khil M., Stricker H., Peabody J., Menon M., DePeralta-Venturina M., Nafziger D., Pegg J., Paielli D., Brown S.et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 62:2002;4968-4976.
10. Fu X., Zhang X. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Res. 62:2002;2306-2312.
11. Goodrum F.D., Ornelles D.A. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. J. Virol. 72:1998;9479-9490.
12. Gromeier M., Lachmann S., Rosenfeld M.R., Gutin P.H., Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl. Acad. Sci. USA. 97:2000;6803-6808.
13. Hecht J.R., Bedford R., Abbruzzese J.L., Lahoti S., Reid T.R., Soetikno R.M., Kirn D.H., Freeman S.M. A Phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin. Cancer Res. 9:2003;555-561.
14. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3:1997;639-645.
15. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., Hawkins L., Kirn D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6:2000;1134-1139.
16. Ichikawa T., Petros W.P., Ludeman S.M., Fangmeier J., Hochberg F.H., Colvin O.M., Chiocca E.A. Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector. Cancer Res. 61:2001;864-868.
17. Ikeda K., Ichikawa T., Wakimoto H., Silver J.S., Deisboeck T.S., Finkelstein D., Harsh G.R., Louis D.N., Bartus R.T., Hochberg F.H., Chiocca E.A. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5:1999;881-887.
18. Ikeda K., Wakimoto H., Ichikawa T., Jhung S., Hochberg F.H., Louis D.N., Chiocca E.A. Complement depletion facilitates the infection of multiple brain tumors by an intravascular, replication-conditional herpes simplex virus mutant. J. Virol. 74:2000;4765-4775.
19. Jee Y.S., Lee S.G., Lee J.C., Kim M.J., Lee J.J., Kim D.Y., Park S.W., Sung M.W., Heo D.S. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. Anticancer Res. 22:2002;2629-2634.
20. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., Gore M., Ironside J., MacDougall R.H., Heise C.et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6:2000;879-885.
21. Lin T., Gu J., Zhang L., Huang X., Stephens L.C., Curley S.A., Fang B. Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res. 62:2002;3620-3625.
22. Liu F.F. Novel gene therapy approach for nasopharyngeal carcinoma. Semin. Cancer Biol. 12:2002;505-515.
23. Logg C.R., Logg A., Matusik R.J., Bochner B.H., Kasahara N. Tissue-specific transcriptional targeting of a replication-competent retroviral vector. J. Virol. 76:2002;12783-12791.
24. Markert J.M., Medlock M.D., Rabkin S.D., Gillespie G.Y., Todo T., Hunter W.D., Palmer C.A., Feigenbaum F., Tornatore C., Tufaro F., Martuza R.L. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma. results of a phase I trial Gene Ther. 7:2000;867-874.
25. Morris J.C., Wildner O. Therapy of head and neck squamous cell carcinoma with an oncolytic adenovirus expressing HSV-tk. Mol. Ther. 1:2000;56-62.
26. Nahde T., Muller K., Fahr A., Muller R., Brusselbach S. Combined transductional and transcriptional targeting of melanoma cells by artificial virus-like particles. J. Gene Med. 3:2001;353-361.
27. Nemunaitis J., Cunningham C., Buchanan A., Blackburn A., Edelman G., Maples P., Netto G., Tong A., Randlev B., Olson S., Kirn D. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients. safety, feasibility and biological activity Gene Ther. 8:2001;746-759. a.
28. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., Kuhn J., McCarty T., Landers S., Blackburn A.et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19:2001;289-298. b.
29. Nemunaitis J., Cunningham C., Tong A.W., Post L., Netto G., Paulson A.S., Rich D., Blackburn A., Sands B., Gibson B.et al. Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients. Cancer Gene Ther. 10:2003;341-352.
30. Pecora A.L., Rizvi N., Cohen G.I., Meropol N.J., Sterman D., Marshall J.L., Goldberg S., Gross P., O'Neil J.D., Groene W.S.et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20:2002;2251-2266.
31. Peng K.W., Donovan K.A., Schneider U., Cattaneo R., Lust J.A., Russell S.J. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood. 101:2003;2557-2562.
32. Qiao J., Doubrovin M., Sauter B.V., Huang Y., Guo Z.S., Balatoni J., Akhurst T., Blasberg R.G., Tjuvajev J.G., Chen S.H., Woo S.L. Tumor-specific transcriptional targeting of suicide gene therapy. Gene Ther. 9:2002;168-175.
33. Rasmussen H., Rasmussen C., Lempicki M., Durham R., Brough D., King C.R., Weichselbaum R. TNFerade Biologic. preclinical toxicology of a novel adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene Cancer Gene Ther. 9:2002;951-957.
34. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., Randlev B., Heise C., Uprichard M., Hatfield M.et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520). phase II viral, immunologic, and clinical endpoints Cancer Res. 62:2002;6070-6079.
35. Samuel C.E. Interferon-induced proteins and their mechanisms of action. Hokkaido Igaku Zasshi. 69:1994;1339-1347.
36. Savontaus M.J., Sauter B.V., Huang T.G., Woo S.L. Transcriptional targeting of conditionally replicating adenovirus to dividing endothelial cells. Gene Ther. 9:2002;972-979.
37. Schneider U., von Messling V., Devaux P., Cattaneo R. Efficiency of measles virus entry and dissemination through different receptors. J. Virol. 76:2002;7460-7467.
38. Shariat S.F., Desai S., Song W., Khan T., Zhao J., Nguyen C., Foster B.A., Greenberg N., Spencer D.M., Slawin K.M. Adenovirus-mediated transfer of inducible caspases. a novel "death switch" gene therapeutic approach to prostate cancer Cancer Res. 61:2001;2562-2571.
39. Shen Y., Kitzes G., Nye J.A., Fattaey A., Hermiston T. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein. J. Virol. 75:2001;4297-4307.
40. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6:2000;821-825.
41. Sze D.Y., Freeman S.M., Slonim S.M., Samuels S.L., Andrews J.C., Hicks M., Ahrar K., Gupta S., Reid T.R. Dr. Gary J. Becker Young Investigator Award. Intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival J. Vasc. Interv. Radiol. 14:2003;279-291.
42. Todo T., Martuza R.L., Rabkin S.D., Johnson P.A. Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. USA. 98:2001;6396-6401.
43. Toth K., Tarakanova V., Doronin K., Ward P., Kuppuswamy M., Locke J.E., Dawson J.E., Kim H.J., Wold W.S. Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein. Cancer Gene Ther. 10:2003;193-200.
44. Varghese S., Rabkin S.D. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther. 9:2002;967-978.
45. Wakimoto H., Ikeda K., Abe T., Ichikawa T., Hochberg F.H., Ezekowitz R.A., Pasternack M.S., Chiocca E.A. The complement response against an oncolytic virus is species-specific in its activation pathways. Mol. Ther. 5:2002;275-282.
46. Wu H., Seki T., Dmitriev I., Uil T., Kashentseva E., Han T., Curiel D.T. Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum. Gene Ther. 13:2002;1647-1653.